SCHEMBL892989

SCHEMBL892989

NCCCc1c[nH]c2ccc(Cl)cc12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 8/20 0.82
TRPM8 Q7Z2W7 3/20 0.82
MPO P05164 5/20 0.68
SLC6A4 P31645 3/20 0.67
GPR84 Q9NQS5 1/20 0.65
GFER P55789 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
KMT2A Q03164 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
HTR1D P28221 3/20 0.55
HTR1A P08908 2/20 0.55
HTR1B P28222 2/20 0.55
HTR2C P28335 2/20 0.55
HTR1E P28566 2/20 0.55
HTR7 P34969 2/20 0.55
DRD3 P35462 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626030 0.90 HTR2A (1.00) HTR2ATRPM8MPOSLC6A4GPR84
SCHEMBL30724496 0.90 HTR2A (1.00) HTR2ATRPM8MPOSLC6A4GPR84
Methane SCHEMBL26617454 0.89 HTR2A (0.97) HTR2ATRPM8MPOSLC6A4GPR84
Hydrochloric Acid SCHEMBL892839 0.89 HTR2A (0.97) HTR2ATRPM8MPOSLC6A4GPR84
Hydrochloric Acid SCHEMBL686594 0.89 HTR2A (0.97) HTR2ATRPM8MPOSLC6A4GPR84
Cyanide SCHEMBL28680847 0.86 HTR2A (0.91) HTR2ATRPM8MPOSLC6A4GPR84
SCHEMBL15676249 0.85 HTR2A (0.69) HTR2ATRPM8SLC6A4GPR84GFER
SCHEMBL8808469 0.84 SLC6A4 (0.67) HTR2ATRPM8MPOSLC6A4GPR84
SCHEMBL892282 0.84 SLC6A4 (0.67) HTR2ATRPM8SLC6A4GPR84GFER
SCHEMBL28117188 0.84 SLC6A4 (0.71) HTR2ATRPM8MPOSLC6A4GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583818-B2 Compound, preparation method thereof, and use thereof DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2026-03-24 US disclosed
EP-4065553-B1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) 2025-01-29 EP disclosed
CN-114981241-B Novel compounds, process for their preparation and their use 大邱庆北尖端医疗产业振兴财团 2024-11-19 CN disclosed
US-20230142654-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF PIMEDBIO, INC. (KR) 2023-05-11 US disclosed
EP-4065553-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2022-10-05 EP disclosed
CN-114981241-A Novel compound, preparation method and application thereof 大邱庆北尖端医疗产业振兴财团 2022-08-30 CN disclosed
WO-2021145729-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2021-07-22 WO disclosed
EP-3190109-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2020-02-19 EP disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-11-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
US-20130289033-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-31 US disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
EP-2651887-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
WO-2012080220-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583818-B2 Compound, preparation method thereof, and use thereof TYRO3, TH, SRMS HTR2A 532/4885TRPM8 3299/4885MPO 1781/4885
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN HTR2A 106/4885TRPM8 1477/4885MPO 2541/4885
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 HTR2A 1488/4885TRPM8 1909/4885MPO 2269/4885
US-20130289033-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 HTR2A 1282/4885TRPM8 1867/4885MPO 2227/4885
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases SNCA, MAPT, NLN HTR2A 106/4885TRPM8 1477/4885MPO 2541/4885
US-20230142654-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF TYR, TYRO3, TH HTR2A 1526/4885TRPM8 4248/4885MPO 841/4885
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases SNCA, MAPT, NLN HTR2A 112/4885TRPM8 1521/4885MPO 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.